Systemic Lupus Erythematosus Market Size, Share & Trends Analysis Report by Drug Class (Immunosuppressants, Biologics, Antimalarials, NSAIDs, Corticosteroids), By Route of Administration, and Segment Forecasts 2018 - 2025
This report can be delivered to the clients within 24 Business hours
The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. Certain new promising drugs that are currently in Phase III trials are anticipated to augment the market as these drugs may target the lupus nephritis patient subset with few effective alternatives and significant unmet needs to be met. This factor is likely to have a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus nephritis.
Use of approved biologic, Benlysta, through clinical studies, has revealed drastic improvements and substantial decrease in consumption of anti-inflammatory glucocorticoids in moderate SLE cases. GSK’s current initiatives center on further increasing opportunities for Benlysta. The company is conducting indication expansion clinical trials, combination therapy studies with rituximab, and new product development, to widen opportunities for its therapy. In this direction, recent launch of Benlysta’s subcutaneous formulation in several countries is expected to boost the SLE market over the forecast period.
Further key findings from the study suggest:
The global systemic lupus erythematosus market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. Certain new promising drugs that are currently in Phase III trials are anticipated to augment the market as these drugs may target the lupus nephritis patient subset with few effective alternatives and significant unmet needs to be met. This factor is likely to have a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus nephritis.
Use of approved biologic, Benlysta, through clinical studies, has revealed drastic improvements and substantial decrease in consumption of anti-inflammatory glucocorticoids in moderate SLE cases. GSK’s current initiatives center on further increasing opportunities for Benlysta. The company is conducting indication expansion clinical trials, combination therapy studies with rituximab, and new product development, to widen opportunities for its therapy. In this direction, recent launch of Benlysta’s subcutaneous formulation in several countries is expected to boost the SLE market over the forecast period.
Further key findings from the study suggest:
- North America was the major contributor for the SLE market revenue in 2017 and is anticipated to rise at a CAGR of 8.1% during the forecast period. This is due to availability of reimbursement and better healthcare infrastructure and accessibility to biologics.
- Europe was ranked as the second largest regional market in the SLE market in 2017 and is expected to register a CAGR of 5.5% over the forecast period
- Immunosuppressants held the largest share in the market in 2017 due to their low cost and high accessibility, whereas the biologics segment is projected to post the highest CAGR during the same period
- In 2017, the oral segment held the dominant share of over 54.0% in the market, followed by the intravenous segment that requires trained medical personnel for administration. Over the forecast years, the latter is poised to expand at a CAGR of 10.4%
- Key players in this space include GlaxoSmithKline, Roche, Pfizer, Novartis, Bayer, and Sanofi. By 2025, other companies such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca are anticipated to enter the SLE market.
CHAPTER 1 REPORT SCOPE
1.1 Segment Market Scope
1.2 Regional Scope
1.3 Estimates & Forecast Timeline
CHAPTER 2 RESEARCH METHODOLOGY
2.1 Model Details
2.1.1 Regression And Variable Analysis
2.2 Information Procurement
2.2.1 List Of Secondary Sources
2.3 List Of Primary Sources
2.4 Purchased Database:
2.5 Gvr’s Internal Database
2.6 Primary Interview Breakup
2.6.1 Data For Primary Interviews, By Sources
2.6.2 Data For Primary Interviews, By Region
CHAPTER 3 REPORT OBJECTIVES
3.1 Objectives
CHAPTER 4 EXECUTIVE SUMMARY
4.1 Market Summary
4.1.1 Industry Analysis - Porter’s
CHAPTER 5 MARKET DEFINITIONS
CHAPTER 6 INDUSTRY OUTLOOK
6.1 Business Segment Trend Analysis
6.2 Pricing Analysis
6.3 Market Variable Analysis
6.3.1 Market Driver Analysis
6.3.1.1 SLE - Specific Curatives In The Development Pipeline Expected To Boost Market Growth
6.3.1.2 Growing Diagnosed Prevalence Is Expected To Foster The Systemic Lupus Erythematosus Market
6.3.2 Market Restraints Analysis
6.3.2.1 High-Cost Treatment Hinders The Growth Of Systemic Lupus Erythematosus Market
6.4 Business Environment Analysis Tools
6.4.1 SLE Market - Swot Analysis, By Factor (Political & Legal, Economic And Technological)
6.4.2 Penetration & Growth Prospect Mapping By Drug Classes, 2017
CHAPTER 7 REGULATORY & POLITICAL FORCES
7.1 Regulatory Landscape
7.1.1 North America
7.1.1.1 U.S.
7.1.1.2 Canada
7.1.2 Europe
7.1.3 Asia Pacific
7.1.4 Latin America
7.1.5 Middle East And Africa
CHAPTER 8 COMPETITIVE & VENDOR LANDSCAPE
8.1 Market Participation Categorization
8.1.1 Market Leader
8.1.2 Innovators
8.2 Strategic Initiatives & Outcome Analysis
8.2.1 List Of Key Strategies, By Company
8.3 List Of Key Companies, By Region
8.4 List Of Key Companies, By Molecule Type
8.5 List Of Key Companies, By Drug Class
8.6 List Of Key Companies, By Roa
8.7 Company Market Share Analysis
CHAPTER 9 SLE MARKET: DRUG CLASS ANALYSIS
9.1 Drug Classes Business Analysis
9.1.1 Immunosuppressants
9.1.1.1 Immunosuppressants Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.2 Nsaids
9.1.2.1 Nsaids Market Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.3 Antimalarials
9.1.3.1 Antimalarials Market Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.4 Biologics
9.1.4.1 Biologics Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.5 Corticosteroids
9.1.5.1 Corticosteroids Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.5.2 SLE Market: Roa Analysis
9.2 Roa Business Analysis
9.2.1 Oral
9.2.1.1 Oral Market Estimates And Forecasts, 2014 - 2025 (USD Million)
9.2.2 Intravenous
9.2.2.1 Intravenous Market Estimates And Forecasts, 2014 - 2025 (USD Million)
9.2.3 Subcutaneous
9.2.3.1 Subcutaneous Market Estimates And Forecasts, 2014 - 2025 (USD Million)
CHAPTER 10 SLE MARKET: REGIONAL ANALYSIS
10.1 North America
10.1.1 North America SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.1.2 U.S.
10.1.2.1 U.S. SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.1.3 Canada
10.1.3.1 Canada SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2 Europe
10.2.1 Europe SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.2 Uk
10.2.2.1 Uk SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.3 Germany
10.2.3.1 Germany SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.4 France
10.2.4.1 France SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.5 Italy
10.2.5.1 Italy SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.6 Poland
10.2.6.1 Poland SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.7 Sweden
10.2.7.1 Sweden SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.8 Spain
10.2.8.1 Spain SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.9 Greece
10.2.9.1 Greece SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3 Asia Pacific
10.3.1 Asia Pacific SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.2 Japan
10.3.2.1 Japan SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.3 China And Hongkong
10.3.3.1 China SLE Drugs Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.3.2 Hong Kong SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.4 India
10.3.4.1 India SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.5 South Korea
10.3.5.1 South Korea SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.6 Singapore & Malaysia
10.3.6.1 Singapore SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.6.2 Malaysia SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.7 Newzealand And Australia
10.3.7.1 New Zealand SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.7.2 Australia SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.8 Taiwan
10.3.8.1 Taiwan SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.4 Latam
10.4.1 Latam SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.4.2 Brazil
10.4.2.1 Brazil SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.4.3 Argentina
10.4.3.1 Argentina SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.4.4 Mexico
10.4.4.1 Mexico SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5 Mea
10.5.1 Mea SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2 Saudi Arabia
10.5.2.1 Saudi Arabia SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2.2 Turkey SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2.3 Kuwait SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2.4 Israel SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2.5 South Africa SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
CHAPTER 11 COMPANY PROFILES
11.1 Key Company Profiled
11.1.1 Glaxosmithkline
11.1.1.1 Company Overview
11.1.1.2 Financial Performance
11.1.1.3 Product Overview
11.1.1.4 Business Strategies
11.1.1.5 Swot Analysis
11.1.2 Roche
11.1.2.1 Company Overview
11.1.2.2 Financial Performance
11.1.2.3 Product Overview
11.1.2.4 Business Strategies
11.1.2.5 Swot Analysis
11.1.3 Pfizer
11.1.3.1 Company Overview
11.1.3.2 Financial Performance
11.1.3.3 Product Overview
11.1.3.4 Business Strategies
11.1.3.5 Swot Analysis
11.1.4 Novartis
11.1.4.1 Company Overview
11.1.4.2 Financial Performance
11.1.4.3 Product Overview
11.1.4.4 Business Strategies
11.1.4.5 Swot Analysis
11.1.5 Bayer
11.1.5.1 Company Overview
11.1.5.2 Financial Performance
11.1.5.3 Product Overview
11.1.5.4 Business Strategies
11.1.5.5 Swot Analysis
11.1.6 Sanofi
11.1.6.1 Company Overview
11.1.6.2 Financial Performance
11.1.6.3 Product Overview
11.1.6.4 Business Strategies
11.1.6.5 Swot Analysis
CHAPTER 12 PIPELINE ANALYSIS
12.1 Promising Therapies
12.2 Future Key Players
CHAPTER 13 RECOMMENDATIONS
1.1 Segment Market Scope
1.2 Regional Scope
1.3 Estimates & Forecast Timeline
CHAPTER 2 RESEARCH METHODOLOGY
2.1 Model Details
2.1.1 Regression And Variable Analysis
2.2 Information Procurement
2.2.1 List Of Secondary Sources
2.3 List Of Primary Sources
2.4 Purchased Database:
2.5 Gvr’s Internal Database
2.6 Primary Interview Breakup
2.6.1 Data For Primary Interviews, By Sources
2.6.2 Data For Primary Interviews, By Region
CHAPTER 3 REPORT OBJECTIVES
3.1 Objectives
CHAPTER 4 EXECUTIVE SUMMARY
4.1 Market Summary
4.1.1 Industry Analysis - Porter’s
CHAPTER 5 MARKET DEFINITIONS
CHAPTER 6 INDUSTRY OUTLOOK
6.1 Business Segment Trend Analysis
6.2 Pricing Analysis
6.3 Market Variable Analysis
6.3.1 Market Driver Analysis
6.3.1.1 SLE - Specific Curatives In The Development Pipeline Expected To Boost Market Growth
6.3.1.2 Growing Diagnosed Prevalence Is Expected To Foster The Systemic Lupus Erythematosus Market
6.3.2 Market Restraints Analysis
6.3.2.1 High-Cost Treatment Hinders The Growth Of Systemic Lupus Erythematosus Market
6.4 Business Environment Analysis Tools
6.4.1 SLE Market - Swot Analysis, By Factor (Political & Legal, Economic And Technological)
6.4.2 Penetration & Growth Prospect Mapping By Drug Classes, 2017
CHAPTER 7 REGULATORY & POLITICAL FORCES
7.1 Regulatory Landscape
7.1.1 North America
7.1.1.1 U.S.
7.1.1.2 Canada
7.1.2 Europe
7.1.3 Asia Pacific
7.1.4 Latin America
7.1.5 Middle East And Africa
CHAPTER 8 COMPETITIVE & VENDOR LANDSCAPE
8.1 Market Participation Categorization
8.1.1 Market Leader
8.1.2 Innovators
8.2 Strategic Initiatives & Outcome Analysis
8.2.1 List Of Key Strategies, By Company
8.3 List Of Key Companies, By Region
8.4 List Of Key Companies, By Molecule Type
8.5 List Of Key Companies, By Drug Class
8.6 List Of Key Companies, By Roa
8.7 Company Market Share Analysis
CHAPTER 9 SLE MARKET: DRUG CLASS ANALYSIS
9.1 Drug Classes Business Analysis
9.1.1 Immunosuppressants
9.1.1.1 Immunosuppressants Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.2 Nsaids
9.1.2.1 Nsaids Market Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.3 Antimalarials
9.1.3.1 Antimalarials Market Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.4 Biologics
9.1.4.1 Biologics Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.5 Corticosteroids
9.1.5.1 Corticosteroids Estimates And Forecasts, 2014 - 2025 (USD Million)
9.1.5.2 SLE Market: Roa Analysis
9.2 Roa Business Analysis
9.2.1 Oral
9.2.1.1 Oral Market Estimates And Forecasts, 2014 - 2025 (USD Million)
9.2.2 Intravenous
9.2.2.1 Intravenous Market Estimates And Forecasts, 2014 - 2025 (USD Million)
9.2.3 Subcutaneous
9.2.3.1 Subcutaneous Market Estimates And Forecasts, 2014 - 2025 (USD Million)
CHAPTER 10 SLE MARKET: REGIONAL ANALYSIS
10.1 North America
10.1.1 North America SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.1.2 U.S.
10.1.2.1 U.S. SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.1.3 Canada
10.1.3.1 Canada SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2 Europe
10.2.1 Europe SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.2 Uk
10.2.2.1 Uk SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.3 Germany
10.2.3.1 Germany SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.4 France
10.2.4.1 France SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.5 Italy
10.2.5.1 Italy SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.6 Poland
10.2.6.1 Poland SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.7 Sweden
10.2.7.1 Sweden SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.8 Spain
10.2.8.1 Spain SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.2.9 Greece
10.2.9.1 Greece SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3 Asia Pacific
10.3.1 Asia Pacific SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.2 Japan
10.3.2.1 Japan SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.3 China And Hongkong
10.3.3.1 China SLE Drugs Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.3.2 Hong Kong SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.4 India
10.3.4.1 India SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.5 South Korea
10.3.5.1 South Korea SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.6 Singapore & Malaysia
10.3.6.1 Singapore SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.6.2 Malaysia SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.7 Newzealand And Australia
10.3.7.1 New Zealand SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.7.2 Australia SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.3.8 Taiwan
10.3.8.1 Taiwan SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.4 Latam
10.4.1 Latam SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.4.2 Brazil
10.4.2.1 Brazil SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.4.3 Argentina
10.4.3.1 Argentina SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.4.4 Mexico
10.4.4.1 Mexico SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5 Mea
10.5.1 Mea SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2 Saudi Arabia
10.5.2.1 Saudi Arabia SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2.2 Turkey SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2.3 Kuwait SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2.4 Israel SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
10.5.2.5 South Africa SLE Market Estimates And Forecasts, 2014 - 2025 (USD Million)
CHAPTER 11 COMPANY PROFILES
11.1 Key Company Profiled
11.1.1 Glaxosmithkline
11.1.1.1 Company Overview
11.1.1.2 Financial Performance
11.1.1.3 Product Overview
11.1.1.4 Business Strategies
11.1.1.5 Swot Analysis
11.1.2 Roche
11.1.2.1 Company Overview
11.1.2.2 Financial Performance
11.1.2.3 Product Overview
11.1.2.4 Business Strategies
11.1.2.5 Swot Analysis
11.1.3 Pfizer
11.1.3.1 Company Overview
11.1.3.2 Financial Performance
11.1.3.3 Product Overview
11.1.3.4 Business Strategies
11.1.3.5 Swot Analysis
11.1.4 Novartis
11.1.4.1 Company Overview
11.1.4.2 Financial Performance
11.1.4.3 Product Overview
11.1.4.4 Business Strategies
11.1.4.5 Swot Analysis
11.1.5 Bayer
11.1.5.1 Company Overview
11.1.5.2 Financial Performance
11.1.5.3 Product Overview
11.1.5.4 Business Strategies
11.1.5.5 Swot Analysis
11.1.6 Sanofi
11.1.6.1 Company Overview
11.1.6.2 Financial Performance
11.1.6.3 Product Overview
11.1.6.4 Business Strategies
11.1.6.5 Swot Analysis
CHAPTER 12 PIPELINE ANALYSIS
12.1 Promising Therapies
12.2 Future Key Players
CHAPTER 13 RECOMMENDATIONS
LIST OF TABLES
Table 1 Country share estimation
Table 2 List of companies, by region
Table 3 List of companies, by molecule type
Table 4 List of companies, by drug Class
Table 5 North America SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 6 North America SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 7 U.S. SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 8 U.S. SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 9 Canada SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 10 Canada SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 11 Europe SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 12 Europe SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 13 UK SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 14 UK SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 15 Germany SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 16 Germany SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 17 France SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 18 France SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 19 Italy SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 20 Italy SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 21 Poland SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 22 Poland SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 23 Sweden SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 24 Sweden SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 25 Spain SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 26 Spain SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 27 Norway SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 28 Norway SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 29 Greece SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 30 Greece SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 31 Asia Pacific SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 32 Asia Pacific SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 33 Japan SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 34 Japan SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 35 China SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 36 China SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 37 Hong Kong SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 38 Hong Kong SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 39 India. SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 40 India SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 41 South Korea SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 42 South Korea SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 43 Singapore SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 44 Singapore SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 45 Malaysia SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 46 Malaysia SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 47 New Zealand SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 48 New Zealand SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 49 Australia SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 50 Australia SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 51 Taiwan SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 52 Taiwan SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 53 LATAM SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 54 LATAM market, by route of administration, 2014 - 2025 (USD Million)
Table 55 Brazil SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 56 Brazil SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 57 Argentina SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 58 Argentina SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 59 Mexico SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 60 Mexico SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 61 MEA SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 62 MEA SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 63 Saudi Arabia SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 64 Saudi Arabia SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 65 Turkey SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 66 Turkey SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 67 Kuwait SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 68 Kuwait SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 69 Israel SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 70 Israel SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 71 South Africa SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 72 South Africa SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 1 Country share estimation
Table 2 List of companies, by region
Table 3 List of companies, by molecule type
Table 4 List of companies, by drug Class
Table 5 North America SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 6 North America SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 7 U.S. SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 8 U.S. SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 9 Canada SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 10 Canada SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 11 Europe SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 12 Europe SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 13 UK SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 14 UK SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 15 Germany SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 16 Germany SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 17 France SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 18 France SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 19 Italy SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 20 Italy SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 21 Poland SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 22 Poland SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 23 Sweden SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 24 Sweden SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 25 Spain SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 26 Spain SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 27 Norway SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 28 Norway SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 29 Greece SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 30 Greece SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 31 Asia Pacific SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 32 Asia Pacific SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 33 Japan SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 34 Japan SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 35 China SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 36 China SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 37 Hong Kong SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 38 Hong Kong SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 39 India. SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 40 India SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 41 South Korea SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 42 South Korea SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 43 Singapore SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 44 Singapore SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 45 Malaysia SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 46 Malaysia SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 47 New Zealand SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 48 New Zealand SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 49 Australia SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 50 Australia SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 51 Taiwan SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 52 Taiwan SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 53 LATAM SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 54 LATAM market, by route of administration, 2014 - 2025 (USD Million)
Table 55 Brazil SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 56 Brazil SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 57 Argentina SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 58 Argentina SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 59 Mexico SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 60 Mexico SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 61 MEA SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 62 MEA SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 63 Saudi Arabia SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 64 Saudi Arabia SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 65 Turkey SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 66 Turkey SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 67 Kuwait SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 68 Kuwait SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 69 Israel SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 70 Israel SLE market, by route of administration, 2014 - 2025 (USD Million)
Table 71 South Africa SLE market, by drug classes, 2014 - 2025 (USD Million)
Table 72 South Africa SLE market, by route of administration, 2014 - 2025 (USD Million)
LIST OF FIGURES
Fig.1 Market segmentation
Fig.2 Market research process
Fig.3 Value chain-based sizing & forecasting
Fig.4 QFD modelling for market share assessment
Fig.5 Information procurement
Fig.6 Primary interviews, by sources
Fig.7 Primary interviews, by region
Fig.8 SLE market revenues, 2017, (USD Millions)
Fig.9 Market trends & outlook
Fig.10 Market driver relevance analysis (Current & future impact)
Fig.11 Market driver relevance analysis (Current & future impact)
Fig.12 SLE market - SWOT analysis, by factor (political & legal, economic and technological)
Fig.13 Penetration &growth prospect mapping by delivery mode, 2016
Fig.14 SLE market - Market participation categorization
Fig.15 Strategy framework analysis, 2016
Fig.16 SLE market share (%), 2014 & 2025
Fig.17 SLE market drug classes outlook: Key takeaways
Fig.18 SLE market: Drug classes movement analysis
Fig.19 Global Immunosuppressants market, 2014 - 2025 (USD Million)
Fig.20 Global NSAIDs market, 2014 - 2025 (USD Million)
Fig.21 Global Antimalarials market, 2014 - 2025 (USD Million)
Fig.22 Global Biologics market, 2014 - 2025 (USD Million)
Fig.23 Global Corticosteroids market, 2014 - 2025 (USD Million)
Fig.24 SLE market ROA Outlook: Key takeaways
Fig.25 SLE market: ROA movement analysis
Fig.26 Global Oral market, 2014 - 2025 (USD Million)
Fig.27 Global Intravenous market, 2014 - 2025 (USD Million)
Fig.28 Global Subcutaneous market, 2014 - 2025 (USD Million)
Fig.29 Regional market place: Key takeaways
Fig.30 Regional outlook, 2014-2025(USD Million)
Fig.31 North America SLE market, 2014 - 2025 (USD Million)
Fig.32 U.S. SLE market, 2014 - 2025 (USD Million)
Fig.33 Canada SLE market, 2014 - 2025 (USD Million)
Fig.34 Europe SLE market, 2014 - 2025 (USD Million)
Fig.35 UK SLE market, 2014 - 2025 (USD Million)
Fig.36 Germany SLE market, 2014 - 2025 (USD Million)
Fig.37 France SLE market, 2014 - 2025 (USD Million)
Fig.38 Italy SLE market, 2014 - 2025 (USD Million)
Fig.39 Poland SLE market, 2014 - 2025 (USD Million)
Fig.40 Sweden SLE market, 2014 - 2025 (USD Million)
Fig.41 Spain SLE market, 2014 - 2025 (USD Million)
Fig.42 Norway SLE market, 2014 - 2025 (USD Million)
Fig.43 Greece SLE market, 2014 - 2025 (USD Million)
Fig.44 Asia Pacific SLE market, 2014 - 2025 (USD Million)
Fig.45 Japan SLE market, 2014 - 2025 (USD Million)
Fig.46 China SLE market, 2014 - 2025 (USD Million)
Fig.47 China SLE market, 2014 - 2025 (USD Million)
Fig.48 India SLE market, 2014 - 2025 (USD Million)
Fig.49 South Korea SLE market, 2014 - 2025 (USD Million)
Fig.50 Singapore SLE market, 2014 - 2025 (USD Million)
Fig.51 Singapore SLE market, 2014 - 2025 (USD Million)
Fig.52 New Zealand SLE market, 2014 - 2025 (USD Million)
Fig.53 Australia SLE market, 2014 - 2025 (USD Million)
Fig.54 Taiwan SLE market, 2014 - 2025 (USD Million)
Fig.55 LATAM SLE market, 2014 - 2025 (USD Million)
Fig.56 Brazil SLE market, 2014 - 2025 (USD Million)
Fig.57 Argentina SLE market, 2014 - 2025 (USD Million)
Fig.58 Mexico SLE market, 2014 - 2025 (USD Million)
Fig.59 MEA SLE market, 2014 - 2025 (USD Million)
Fig.60 Saudi Arabia SLE market, 2014 - 2025 (USD Million)
Fig.61 Turkey SLE market, 2014 - 2025 (USD Million)
Fig.62 Kuwait SLE market, 2014 - 2025 (USD Million)
Fig.63 Israel SLE market, 2014 - 2025 (USD Million)
Fig.64 South Africa SLE market, 2014 - 2025 (USD Million)
Fig.65 GlaxoSmithKline - SWOT analysis
Fig.66 Roche - SWOT analysis
Fig.67 Pfizer - SWOT analysis
Fig.68 Novartis - SWOT analysis
Fig.69 Bayer - SWOT analysis
Fig.70 Sanofi - SWOT analysis
Fig.1 Market segmentation
Fig.2 Market research process
Fig.3 Value chain-based sizing & forecasting
Fig.4 QFD modelling for market share assessment
Fig.5 Information procurement
Fig.6 Primary interviews, by sources
Fig.7 Primary interviews, by region
Fig.8 SLE market revenues, 2017, (USD Millions)
Fig.9 Market trends & outlook
Fig.10 Market driver relevance analysis (Current & future impact)
Fig.11 Market driver relevance analysis (Current & future impact)
Fig.12 SLE market - SWOT analysis, by factor (political & legal, economic and technological)
Fig.13 Penetration &growth prospect mapping by delivery mode, 2016
Fig.14 SLE market - Market participation categorization
Fig.15 Strategy framework analysis, 2016
Fig.16 SLE market share (%), 2014 & 2025
Fig.17 SLE market drug classes outlook: Key takeaways
Fig.18 SLE market: Drug classes movement analysis
Fig.19 Global Immunosuppressants market, 2014 - 2025 (USD Million)
Fig.20 Global NSAIDs market, 2014 - 2025 (USD Million)
Fig.21 Global Antimalarials market, 2014 - 2025 (USD Million)
Fig.22 Global Biologics market, 2014 - 2025 (USD Million)
Fig.23 Global Corticosteroids market, 2014 - 2025 (USD Million)
Fig.24 SLE market ROA Outlook: Key takeaways
Fig.25 SLE market: ROA movement analysis
Fig.26 Global Oral market, 2014 - 2025 (USD Million)
Fig.27 Global Intravenous market, 2014 - 2025 (USD Million)
Fig.28 Global Subcutaneous market, 2014 - 2025 (USD Million)
Fig.29 Regional market place: Key takeaways
Fig.30 Regional outlook, 2014-2025(USD Million)
Fig.31 North America SLE market, 2014 - 2025 (USD Million)
Fig.32 U.S. SLE market, 2014 - 2025 (USD Million)
Fig.33 Canada SLE market, 2014 - 2025 (USD Million)
Fig.34 Europe SLE market, 2014 - 2025 (USD Million)
Fig.35 UK SLE market, 2014 - 2025 (USD Million)
Fig.36 Germany SLE market, 2014 - 2025 (USD Million)
Fig.37 France SLE market, 2014 - 2025 (USD Million)
Fig.38 Italy SLE market, 2014 - 2025 (USD Million)
Fig.39 Poland SLE market, 2014 - 2025 (USD Million)
Fig.40 Sweden SLE market, 2014 - 2025 (USD Million)
Fig.41 Spain SLE market, 2014 - 2025 (USD Million)
Fig.42 Norway SLE market, 2014 - 2025 (USD Million)
Fig.43 Greece SLE market, 2014 - 2025 (USD Million)
Fig.44 Asia Pacific SLE market, 2014 - 2025 (USD Million)
Fig.45 Japan SLE market, 2014 - 2025 (USD Million)
Fig.46 China SLE market, 2014 - 2025 (USD Million)
Fig.47 China SLE market, 2014 - 2025 (USD Million)
Fig.48 India SLE market, 2014 - 2025 (USD Million)
Fig.49 South Korea SLE market, 2014 - 2025 (USD Million)
Fig.50 Singapore SLE market, 2014 - 2025 (USD Million)
Fig.51 Singapore SLE market, 2014 - 2025 (USD Million)
Fig.52 New Zealand SLE market, 2014 - 2025 (USD Million)
Fig.53 Australia SLE market, 2014 - 2025 (USD Million)
Fig.54 Taiwan SLE market, 2014 - 2025 (USD Million)
Fig.55 LATAM SLE market, 2014 - 2025 (USD Million)
Fig.56 Brazil SLE market, 2014 - 2025 (USD Million)
Fig.57 Argentina SLE market, 2014 - 2025 (USD Million)
Fig.58 Mexico SLE market, 2014 - 2025 (USD Million)
Fig.59 MEA SLE market, 2014 - 2025 (USD Million)
Fig.60 Saudi Arabia SLE market, 2014 - 2025 (USD Million)
Fig.61 Turkey SLE market, 2014 - 2025 (USD Million)
Fig.62 Kuwait SLE market, 2014 - 2025 (USD Million)
Fig.63 Israel SLE market, 2014 - 2025 (USD Million)
Fig.64 South Africa SLE market, 2014 - 2025 (USD Million)
Fig.65 GlaxoSmithKline - SWOT analysis
Fig.66 Roche - SWOT analysis
Fig.67 Pfizer - SWOT analysis
Fig.68 Novartis - SWOT analysis
Fig.69 Bayer - SWOT analysis
Fig.70 Sanofi - SWOT analysis
